NCT02206308View on ClinicalTrials.gov

Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
B-cell Non Hodgkin's Lymphoma
Interventions
BIOLOGICAL

Chimeric anti-CD20 monoclonal antibody

All Listed Sponsors
lead

Sinocelltech Ltd.

INDUSTRY

NCT02206308 - Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma. | Biotech Hunter | Biotech Hunter